Skip to main content Accessibility help
×
Hostname: page-component-848d4c4894-sjtt6 Total loading time: 0 Render date: 2024-07-07T17:08:26.578Z Has data issue: false hasContentIssue false

4 - Transarterial chemoembolization in the management of primary and secondary liver tumors

Published online by Cambridge University Press:  23 December 2009

Andy Adam
Affiliation:
University of London
Peter R. Mueller
Affiliation:
Massachussets General Hospital, Boston
Get access

Summary

Introduction

Primary and secondary liver tumors are a common cause of morbidity and mortality around the world. While curative therapies for some of these cancers exist – hepatocellular carcinoma (HCC) can be treated with partial hepatectomy or liver transplantation – many patients are ineligible for curative liver resection due to the advanced stage of their cancers; furthermore, widespread implementation of liver transplantation is prevented by a shortage of donor organs. The same is true for patients with metastatic colorectal or neuroendocrine tumors. Due to these shortcomings, various palliative therapies have been advanced in the management of hepatic neoplasms. These include systemic chemotherapy, radiation therapy, and local and regional percutaneous modalities. The latter group comprises both ablative techniques (chemical and thermal), and the intra-arterial embolotherapies.

Unlike healthy hepatocytes, which are supplied largely by the portal venous circulation, both primary and secondary liver tumors receive their vascular supply principally from the hepatic artery. Thus, occlusion of the hepatic artery would be expected to lead to ischemic necrosis of tumor cells while selectively sparing the native liver. This principle has been exploited in the development of bland transarterial embolization (TAE) and transarterial chemoembolization (TACE). In both of these approaches, the branches of the hepatic artery that supply the tumor are occluded with embolic particles. For chemoembolization, chemotherapeutic agents are added to the embolization mixture for delivery directly into the tumor.

In principle, chemoembolization targets liver lesions by a multifaceted attack. First, embolization of the vascular supply triggers localized tissue ischemia.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Konno, T.Targeting cancer chemotherapeutic agents by use of lipiodol contrast medium. Cancer 1990; 66: 1897–903.3.0.CO;2-J>CrossRefGoogle ScholarPubMed
Egawa, H, Maki, A, Mori, K, et al. Effects of intraarterial chemotherapy with a new lipophilic anticancer agent, estradiol-chlorambucil (KM2210), dissolved in lipiodol on experimental liver tumor in rats. J Surg Oncol 1990; 44: 109–14.CrossRefGoogle Scholar
Ramsey, , Kernagis, LY, Soulen, MC, Geschwind, JF.Chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol 2002; 13: S211–21.CrossRefGoogle ScholarPubMed
Nakamura, H, Hashimoto, T, Oi, H, Sawada, S.Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 1989; 170: 783–6.CrossRefGoogle ScholarPubMed
Sasaki, Y, Imaoka, S, Kasugai, H, et al. A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge. Cancer 1987; 60: 1194–203.3.0.CO;2-T>CrossRefGoogle ScholarPubMed
Kruskal, JB, Hlatky, L, Hahnfeldt, P, et al. In-vivo and in-vitro analysis of the effectiveness of doxorubicin combined with temporary arterial occlusion in liver tumors. J Vasc Interv Radiol 1993; 4: 741–8.CrossRefGoogle ScholarPubMed
Leung, DA, Goin, JE, Sickles, C, Soulen, MC.Determinants of post-embolization syndrome following hepatic chemoembolization. J Vasc Interv Radiol 2001; 12: 321–6.CrossRefGoogle Scholar
Marelli, L, Stigliano, R, Triantos, C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30: 6–25.CrossRefGoogle ScholarPubMed
Varela, M, Real, MI, Burrel, M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46: 474–81.CrossRefGoogle ScholarPubMed
Ono, Y, Yoshimasu, T, Ashikaga, R, et al. Long-term results of lipiodol-transcatheter arterial embolization with cisplatin or doxorubicin for unresectable hepatocellular carcinoma. Am J Clin Oncol 2000; 23: 564–8.CrossRefGoogle ScholarPubMed
Takayasu, K, Shima, Y, Muramatsu, Y, et al. Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology 1987; 163: 345–51.CrossRefGoogle ScholarPubMed
Pelletier, G, Roche, A, Ink, O, et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990; 1: 181–4.CrossRefGoogle Scholar
Madden, MV, Krige, JE, Bailey, S, et al. Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma. Gut 1993; 34: 1598–600.CrossRefGoogle ScholarPubMed
,Group d'Etude et de Traitement du Carcinome Hépatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995; 332: 1256–61.CrossRefGoogle Scholar
Lo, CM, Ngan, H, Tso, WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164–71.CrossRefGoogle ScholarPubMed
Llovet, JM, Real, MI, Montana, X, et al. Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 2002; 359: 1734–9.CrossRefGoogle ScholarPubMed
Harada, T, Matsuo, K, Inoue, T, et al. Is preoperative hepatic arterial chemoembolization safe and effective for hepatocellular carcinoma? Ann Surg 1996; 224: 4–9.CrossRefGoogle ScholarPubMed
Majno, PE, Adam, R, Bismuth, H, et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 1997; 226: 688–701.CrossRefGoogle ScholarPubMed
Lesurtel, M, Müllhaupt, B, Pestalozzi, BC, Pfammatter, T, Clavien, PA.Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidence-based analysis. Am J Transplant 2006; 6: 2644–50.CrossRefGoogle ScholarPubMed
Maddala, YK, Stadheim, L, Andrews, JC, et al. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transpl 2004; 10: 449–55.CrossRefGoogle ScholarPubMed
Oldhafer, KJ, Chavan, A, Frühauf, NR, et al. Arterial chemoembolization before liver transplantation in patients with hepatocellular carcinoma: marked tumor necrosis, but no survival benefit? J Hepatol 1998; 29: 953–9.CrossRefGoogle ScholarPubMed
Richard, HM, Silberzweig, JE, Mitty, HA, et al. Hepatic arterial complications in liver transplant recipients treated with pretransplantation chemoembolization for hepatocellular carcinoma. Radiology 2000; 214: 775–9.CrossRefGoogle ScholarPubMed
Di Carlo, V, Ferrari, G, Castoldi, R, et al. Pre-operative chemoembolization of hepatocellular carcinoma in cirrhotic patients. Hepatogastroenterology 1998; 45: 1950–4.Google ScholarPubMed
Zhang, Z, Liu, Q, He, J, et al. The effect of preoperative transcatheter hepatic arterial chemoembolization on disease-free survival after hepatectomy for hepatocellular carcinoma. Cancer 2000; 89: 2606–12.3.0.CO;2-T>CrossRefGoogle ScholarPubMed
Wu, CC, Ho, YZ, Ho, WL, et al. Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal. Br J Surg 1995; 82: 122–6.CrossRefGoogle ScholarPubMed
Schwartz, JD, Schwartz, M, Mandeli, J, Sung, M.Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol 2002; 3: 593–603.CrossRefGoogle ScholarPubMed
Vogl, TJ, Zangos, S, Eichler, K, Yakoub, D, Nabil, M.Colorectal liver metastases: regional chemotherapy via transarterial chemoembolization (TACE) and hepatic chemoperfusion: an update. Eur Radiol 2007; 17: 1025–34.CrossRefGoogle ScholarPubMed
Martinelli, DJ, Wadler, S, Bakal, CW, et al. Utility of embolization or chemoembolization as second-line treatment in patients with advanced or recurrent colorectal carcinoma. Cancer 1994; 74: 1706–12.3.0.CO;2-J>CrossRefGoogle ScholarPubMed
Lang, EK, Brown, CL.Colorectal metastases to the liver: selective chemoembolization. Radiology 1993; 189: 417–22.CrossRefGoogle ScholarPubMed
Taniai, N, Onda, M, Tajiri, T, et al. Good embolization response for colorectal liver metastases with hypervascularity. Hepatogastroenterology 2002; 49: 1531–4.Google ScholarPubMed
Goode, JA, Matson, MB.Embolisation of cancer: what is the evidence? Cancer Imaging 2004; 4: 133–41.CrossRefGoogle ScholarPubMed
Hunt, TM, Flowerdew, AD, Birch, SJ, et al. Prospective randomised trial of hepatic arterial embolization or infusion chemotherapy with 5-fluorouracil and degradable starch microspheres for colorectal liver metastases. Br J Surg 1990; 77: 779–82.Google ScholarPubMed
Salman, HS, Cynamon, J, Jagust, M, et al. Randomized phase II trial of embolization therapy versus chemoembolization therapy in previously treated patients with colorectal carcinoma metastatic to the liver. Clin Colorectal Cancer 2002; 2: 173–9.CrossRefGoogle ScholarPubMed
Kaltsas, GA, Besser, GM, Grossman, AB.The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004; 25: 458–511.CrossRefGoogle ScholarPubMed
Ruszniewski, P, O'Toole, D.Ablative therapies for liver metastases of gastroenteropancreatic endocrine tumors. Neuroendocrinology 2004; 80 (Suppl 1): 74–8.CrossRefGoogle ScholarPubMed
Touzios, JG, Kiely, JM, Pitt, SC, et al. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 2005; 241: 776–83.CrossRefGoogle ScholarPubMed
Ruutiainen, AT, Soulen, MC, Tuite, CM, et al. Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver. J Vasc Interv Radiol 2007; 18: 847–55.CrossRefGoogle ScholarPubMed
Wigmore, SJ, Redhead, DN, Thomson, BN, et al. Postchemoembolisation syndrome: tumour necrosis or hepatocyte injury? Br J Cancer 2003; 89: 1423–7.CrossRefGoogle ScholarPubMed
Chan, AO, Yuen, MF, Hui, CK, Tso, WK, Lai, CL.A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 2001; 94: 1747–52.CrossRefGoogle Scholar
Tarazov, PG, Polysalov, VN, Prozorovskij, KV, Grishchenkova, IV, Rozengauz, EV.Ischemic complications of transcatheter arterial chemoembolization in liver malignancies. Acta Radiol 2000; 41: 156–60.CrossRefGoogle ScholarPubMed
Kim, W, Clark, TW, Baum, RA, Soulen, MC.Risk factors for liver abscess formation after hepatic chemoembolization. J Vasc Interv Radiol 2001; 12: 965–8.CrossRefGoogle ScholarPubMed
Plentz, RR, Lankisch, TO, Basturk, M, et al. Prospective analysis of German patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization with or without prophylactic antibiotic therapy. J Gastroenterol Hepatol 2005; 20: 1134–6.CrossRefGoogle ScholarPubMed
Xia, J, Ren, Z, Ye, S, et al. Study of severe and rare complications of transarterial chemoembolization (TACE) for liver cancer. Eur J Radiol 2006; 59: 407–12.CrossRefGoogle ScholarPubMed
Leung, TK, Lee, CM, Chen, HC.Anatomic and technical skill factor of gastroduodenal complication in post-transarterial embolization for hepatocellular carcinoma: a retrospective cohort study of 280 cases. World J Gastroenterol 2005; 11: 1554–7.CrossRefGoogle ScholarPubMed
Huo, TI, Wu, JC, Lee, PC, Chang, FY, Lee, SD.Incidence and risk factors for acute renal failure in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective study. Liver Int 2004; 24: 210–15.CrossRefGoogle ScholarPubMed
Roullet, MH, Denys, A, Sauvanet, A, et al. [Acute clinical pancreatitis following selective transcatheter arterial chemoembolization of hepatocellular carcinoma.]Ann Chir 1995; 127: 779–82.CrossRefGoogle Scholar
Lopez-Benitez, R, Radeleff, BA, Barragan-Campos, HM, et al. Acute pancreatitis after embolization of liver tumors: frequency and associated risk factors. Pancreatology 2007; 7: 53–62.CrossRefGoogle ScholarPubMed
Pentecost, MJ, Daniels, JR, Teitelbaum, GP, Stanley, P.Hepatic chemoembolization: safety with portal vein thrombosis. J Vasc Intervent Radiol 1993; 4: 347–51.CrossRefGoogle ScholarPubMed
Llado, L, Virgili, J, Figueras, J, et al. A prognostic index of survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Cancer 2000; 88: 50–7.3.0.CO;2-I>CrossRefGoogle ScholarPubMed
Lewis, AL, Gonzalez, MV, Lloyd, AW, et al. DC Bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Intervent Radiol 2006; 17: 335–42.CrossRefGoogle ScholarPubMed
Hong, K, Khwaja, A, Liapi, E, et al. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res 2006; 12: 2563–7.CrossRefGoogle Scholar
Varela, M, Real, MI, Burrel, M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46: 474–81.CrossRefGoogle ScholarPubMed
Poon, RT, Tso, WK, Pang, RW, et al. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 2007; 5: 1100–8.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×